Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00830804 · ClinicalTrials.gov registry record · Phase 2
Safety and Effectiveness of Raltegravir Plus Darunavir/Ritonavir in Treatment-Naive HIV-Infected Adults
A Phase 2 study of HIV-1 Infections, sponsored by Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections.
- Completed
- Registry status
- Phase 2
- Development phase
- 113
- Enrollment target
- 20
- Study locations
NCT00830804 is a Phase 2 study of HIV-1 Infections that has completed, run by Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections. The registered enrollment target is 113 participants. The trial reports 20 study locations across 12 states.
The verdict
NCT00830804, a Phase 2 study of HIV-1 Infections, has completed, sponsored by Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 113 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess the effectiveness and safety of an antiretroviral therapy (ART) regimen consisting of raltegravir (RAL) and darunavir (DRV)/ritonavir (RTV) as first-line therapy in treatment-naïve participants.
Conditions Studied
Interventions
- DRUG Raltegravir
- DRUG Darunavir/Ritonavir
Study Locations (20)
Ohio
- Univ. of Cincinnati CRS - Cincinnati
- Case CRS - Cleveland
- MetroHealth CRS - Cleveland
- The Ohio State Univ. AIDS CRS - Columbus
California
- Stanford CRS - Palo Alto
- Ucsd, Avrc Crs - San Diego
- Ucsf Aids Crs - San Francisco
Massachusetts
- Beth Israel Deaconess Med Center - Boston
- Brigham and Women's Hosp. ACTG CRS - Boston
North Carolina
- Unc Aids Crs - Chapel Hill
- Duke Univ. Med. Ctr. Adult CRS - Durham
Pennsylvania
- Hosp. of the Univ. of Pennsylvania CRS - Philadelphia
- University of Pittsburgh CTU - Pittsburgh
Alabama
- AlabamaTherapeutics CRS - Birmingham
Colorado
- University of Colorado Hospital CRS - Aurora
District of Columbia
- Georgetown University CRS - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 113 participants |
| Start Date | 2009-04 |
| Est. Completion | 2010-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00830804
The ClinicalTrials.gov registry entry for NCT00830804 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 113 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, which has 45 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV-1 Infections appearing as the primary indexed condition, and to 2 interventions - of which Raltegravir is the first listed.
NCT00830804 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Ohio, California, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00830804 about?
NCT00830804 is a clinical study titled "Safety and Effectiveness of Raltegravir Plus Darunavir/Ritonavir in Treatment-Naive HIV-Infected Adults". The purpose of this study is to assess the effectiveness and safety of an antiretroviral therapy (ART) regimen consisting of raltegravir (RAL) and darunavir (DRV)/ritonavir (RTV) as first-line therapy in treatment-naïve participants.
What is the current status of trial NCT00830804?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 113 participants. The study started on 2009-04. Estimated completion is 2010-09.
What conditions does trial NCT00830804 study?
This clinical trial studies the following conditions: HIV-1 Infections.
What interventions are being tested in trial NCT00830804?
The interventions under investigation include: Raltegravir (DRUG), Darunavir/Ritonavir (DRUG).
Who is sponsoring clinical trial NCT00830804?
This trial is sponsored by Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, which has 45 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00830804 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, District of Columbia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.